The Global Rotavirus Vaccine Market Size was valued at USD 9,053 Million in 2021 and is predicted to be worth USD 22,750 Million by 2030, with a CAGR of 11% from 2022 to 2030.
Rotavirus is a contagious disease majorly affecting children and infants; watery diarrhea, vomiting, fever, and abdominal pain are some major symptoms witnessed by doctors.
Noticeable increase in number of patients suffering from various infections is resulting in government focus towards creating awareness among consumers related to available medications. Infection such as rotavirus has been impacting the lives of infants & children’s across the globe. Countries with poor resources are witnessing high death ratio. The mortality due to rotavirus across the globe is 600,000 each year and 80% of these deaths occur in less developed and poor countries. Rotavirus gastroenteritis results in only 20 to 70 childhood deaths per year in the United States. Rapid technological advancements in healthcare sector, increasing number of clinical trials by major players for development of new vaccines and increasing government spending on increasing the awareness among consumers are major factors expected to drive the growth of global rotavirus vaccine market. Major players are investing high for the development of new vaccines. Their approach towards decline the child hospitalization rate and lower the cost spent of rotavirus hospitalization. From 2007-2011 on an average annually 280,000 clinic visits, 62,000 emergency department visits, and 45,000 hospitalizations for rotavirus disease were seen in the US of children younger than age 5 years.
Global Rotavirus Vaccine Market DRO’s
Market Drivers
- Growing prevalence of rotavirus infection among children
- The rise in the number of people with weakened immune systems
- An increase in the elderly population
Market Restraints
- Uncertain demand from non-GAVI MICs
- Concerns about the vaccinations' negative effects
Market Opportunity
- Increase in the overall population and live births
Report Coverage
Market |
Rotavirus Vaccine Market |
Market Size 2021 |
USD 9,053 Million |
Market Forecast 2030 |
USD 22,750 Million |
CAGR During 2022 - 2030 |
11% |
Analysis Period |
2018 - 2030 |
Base Year |
2021 |
Forecast Data |
2022 - 2030 |
Segments Covered |
By Type, By End-Use, And By Geography
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Key Companies Profiled |
BIOVIRx Inc, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Bharat Biotech, Biological E, Bio Farma, Novartis AG, GlaxoSmithKline plc., Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd, Berghofer Medical Research Institute, and Pfizer, Inc. |
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
Customization Scope |
10 hrs of free customization and expert consultation
|
Rotavirus Vaccine Market Dynamics
Players are focused on enhancing the business through new product launches and acquisitions. Their approach towards securing long time contracts in order to enhance the revenue share are factors expected to impact the growth of rotavirus vaccine market value. In 2021, GSK a global drugs manufacturer signed a contract with UNICEF to supply its rotavirus vaccine, Rotarix, through the Humanitarian Mechanism for civil society organizations serving the vaccination needs of refugee and other emergency situations. In 2021, Bharat Biotech, a global drug developer received award “BioSpectrum Product of the Year Award 2020” for its rotavirus vaccine, “ROTAVAC 5D”. The vaccine is safe and effective in the prevention of rotavirus diarrhea. This is expected to help company attract new customers and increase product sale. Factors such as high cost associated to vaccine development and strict government regulations related to product approval are factors expected to hamper the growth of global rotavirus vaccine market size. The drug regulatory bodies are implementing stringent regulations for the approval of drugs. In 2010, The US Food and Drug Administration (FDA), in public meeting advised healthcare practitioners to temporarily stop using of GlaxoSmithKline's (GSK's) Rotarix rotavirus vaccine. The vaccine has presence of porcine circovirus 1 (PCV1) in the product which is harmful. In addition, high price of vaccine for the low economic growth countries is expected to challenge the rotavirus vaccine market growth. However, increasing investment for drug development from major players and development of low cost vaccines are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, increasing partnership and contract between private and public enterprises is expected to support the revenue transaction of target market.
Rotavirus Vaccine Market Segmentation
The global rotavirus vaccine market segmentation based on the type, end-use and geographical region. The type segment is divided into Lanzhou Lamb, Rotarix, Rotavac, Rotavin-M1, and others. The end-use segment is bifurcated into hospitals, clinics, and academic & research lab. Among end-use the hospital segment is expected to account for major revenue share in the global market.
Market by Type
- Lanzhou Lamb
- Rotarix
- Rotavac
- Rotavin-M1
- Others
Market by End-Use
- Hospitals
- Clinics
- Academic & Research Lab
Rotavirus Vaccine Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
The Middle East & Africa (MEA)
- Gulf Cooperation Council (GCC)
- South Africa
- Rest of the Middle East & Africa
The Extensive Use of Pharmaceuticals and Rising Health-Care Spending in North America, Drives Regional Market Growth
The market in North America is expected to account for major revenue share in the global rotavirus vaccine market due to wide adoption of the vaccines from consumers. In addition, availability of advanced R&D infrastructure in the country and high government spending on development of healthcare sector are factors expected to support the growth of target market. Standard healthcare regulatory scenario, rising awareness activities and implementation of various vaccination programs by the government is expected to impact the growth of regional market.
Rotavirus Vaccine Market Players
The global rotavirus vaccine market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Some of the prominent global rotavirus vaccine market companies are BIOVIRx Inc, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Bharat Biotech, Biological E, Bio Farma, Novartis AG, GlaxoSmithKline plc., Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd, Berghofer Medical Research Institute, and Pfizer, Inc.
CHAPTER 1. Industry Overview of Rotavirus Vaccine Market
1.1. Definition and Scope
1.1.1. Definition of Rotavirus Vaccine
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Rotavirus Vaccine Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Rotavirus Vaccine Market By Type
1.2.3. Rotavirus Vaccine Market By End-Use
1.2.4. Rotavirus Vaccine Market By Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Rotavirus Vaccine Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Rotavirus Vaccine Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Cost Structure Analysis
3.9.1. Price Trend of Key Raw Materials
3.9.2. Raw Material Suppliers
3.9.3. Proportion of Manufacturing Cost Structure
3.9.3.1. Raw Material Cost
3.9.3.2. Labor Cost
3.9.3.3. Manufacturing Expense
3.10. Competitive Landscape, 2021
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2021
4.2. R&D Status of Major Manufacturers in 2021
CHAPTER 5. Rotavirus Vaccine Market Revenue By Type
5.1. Introduction
5.2. Rotavirus Vaccine Market Revenue (USD Million) By Type
5.2.1. Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
5.2.2. Lanzhou Lamb
5.2.2.1. Lanzhou Lamb Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.3. Rotarix
5.2.3.1. Rotarix Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.4. Rotavac
5.2.4.1. Rotavac Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.5. Rotavin-M1
5.2.5.1. Rotavin-M1 Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.6. Others
5.2.6.1. Others Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 6. Rotavirus Vaccine Market Revenue By End-Use
6.1. Introduction
6.2. Rotavirus Vaccine Market Revenue (USD Million) By End-Use
6.2.1. Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
6.2.2. Hospitals
6.2.2.1. Hospitals Market Revenue (USD Million) and Growth Rate (%), 2018-2030
6.2.3. Clinics
6.2.3.1. Clinics Market Revenue (USD Million) and Growth Rate (%), 2018-2030
6.2.4. Academic & Research Lab
6.2.4.1. Academic & Research Lab Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 7. North America Rotavirus Vaccine Market By Country
7.1. North America Rotavirus Vaccine Market Overview
7.2. U.S.
7.2.1. U.S. Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
7.2.2. U.S. Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
7.3. Canada
7.3.1. Canada Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
7.3.2. Canada Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
7.4. North America PEST Analysis
CHAPTER 8. Europe Rotavirus Vaccine Market By Country
8.1. Europe Rotavirus Vaccine Market Overview
8.2. U.K.
8.2.1. U.K. Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
8.2.2. U.K. Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
8.3. Germany
8.3.1. Germany Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
8.3.2. Germany Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
8.4. France
8.4.1. France Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
8.4.2. France Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
8.5. Spain
8.5.1. Spain Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
8.5.2. Spain Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
8.6. Rest of Europe
8.6.1. Rest of Europe Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
8.6.2. Rest of Europe Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
8.7. Europe PEST Analysis
CHAPTER 9. Asia-Pacific Rotavirus Vaccine Market By Country
9.1. Asia-Pacific Rotavirus Vaccine Market Overview
9.2. China
9.2.1. China Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
9.2.2. China Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
9.3. Japan
9.3.1. Japan Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
9.3.2. Japan Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
9.4. India
9.4.1. India Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
9.4.2. India Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
9.5. Australia
9.5.1. Australia Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
9.5.2. Australia Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
9.6. South Korea
9.6.1. South Korea Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
9.6.2. South Korea Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
9.7.2. Rest of Asia-Pacific Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Rotavirus Vaccine Market By Country
10.1. Latin America Rotavirus Vaccine Market Overview
10.2. Brazil
10.2.1. Brazil Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
10.2.2. Brazil Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
10.3. Mexico
10.3.1. Mexico Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
10.3.2. Mexico Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
10.4. Rest of Latin America
10.4.1. Rest of Latin America Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
10.4.2. Rest of Latin America Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Rotavirus Vaccine Market By Country
11.1. Middle East & Africa Rotavirus Vaccine Market Overview
11.2. GCC
11.2.1. GCC Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
11.2.2. GCC Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
11.3. South Africa
11.3.1. South Africa Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
11.3.2. South Africa Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Rotavirus Vaccine Market Revenue (USD Million) and Forecast By Type, 2018-2030
11.4.2. Rest of Middle East & Africa Rotavirus Vaccine Market Revenue (USD Million) and Forecast By End-Use, 2018-2030
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Rotavirus Vaccine Market
12.1. Rotavirus Vaccine Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking of Key Players by Price, Presence, Market Share, and R&D Investment
12.2.2. Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Rotavirus Vaccine Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. BIOVIRx Inc
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Market Revenue (USD Million), 2021
13.1.3.2. BIOVIRx Inc 2021 Rotavirus Vaccine Business Regional Distribution
13.1.4. Product/service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Serum Institute of India Pvt. Ltd.
13.3. Merck & Co., Inc.
13.4. Bharat Biotech
13.5. Biological E
13.6. Bio Farma
13.7. Novartis AG
13.8. GlaxoSmithKline plc.
13.9. Sanofi
13.10. Lanzhou Institute of Biologicals Products Co., Ltd
13.11. Berghofer Medical Research Institute
13.12. Pfizer, Inc.